SEATTLE, WA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)RIVKIN CENTER FOR OVARIAN CANCER, founded in 1996, is a community nonprofit in the Medical Research sector that reported $1.7M in total revenue in fiscal year 2024. Revenue surged 32% from the prior year, signaling strong growth momentum.
WE ENVISION A WORLD WHERE WOMEN LIVE LONGER AND HEALTHIER LIVES BECAUSE OVARIAN CANCER CAN BE PREVENTED, CAUGHT EARLY, OR CURED.
THE RIVKIN CENTER'S PROGRAMMATIC WORK UNDERWENT DYNAMIC CHANGE IN 2024, AND EVEN BIGGER CHANGES ARE COMING FOR 2025.FOR THREE DECADES, THE RIVKIN CENTER'S SCIENTIFIC GRANT PROGRAM HAS USED A...
THE RIVKIN CENTER'S PROGRAMMATIC WORK UNDERWENT DYNAMIC CHANGE IN 2024, AND EVEN BIGGER CHANGES ARE COMING FOR 2025.FOR THREE DECADES, THE RIVKIN CENTER'S SCIENTIFIC GRANT PROGRAM HAS USED A SEED-FUNDING APPROACH THAT LAUNCHES PROMISING NEW RESEARCH AND RESEARCHERS THROUGHOUT THE WORLD. AFTER PAUSING NEW GRANTS IN 2023, THE RIVKIN CENTER FUNDED TWO $75K PILOT STUDY AWARDS IN 2024. THE RIVKIN CENTER AND WASHINGTON STATE'S ANDY HILL CANCER RESEARCH ENDOWMENT (CARE) FUND ALSO CREATED A PUBLIC-PRIVATE PARTNERSHIP TO JOINTLY SUPPORT $1M IN OVARIAN CANCER RESEARCH IN WASHINGTON STATE. IN 2024, THE FIRST TWO GRANTS TOTALING $400K WERE AWARDED; $600K IN GRANTS WILL BE AWARDED IN 2025. BY THE END OF 2024, THE RIVKIN CENTER HAD RAISED ITS $500K IN PRIVATE MATCHING FUNDS. OVARIAN CANCER IS UNDERFUNDED BY FEDERAL FUNDING AGENCIES WHEN COMPARED TO OTHER CANCERS, DESPITE IT STILL HAVING NO UNIVERSAL SCREENING TOOL AND BEING THE DEADLIEST GYNECOLOGICAL CANCER. FOR EVERY DOLLAR INVESTED BY THE RIVKIN CENTER, OUR AWARDEES, ON AVERAGE, LEVERAGE ANOTHER $17.30 FROM OTHER FUNDING SOURCES TO FURTHER THEIR OVARIAN CANCER RESEARCH.
IN SEPTEMBER 2024, THE RIVKIN CENTER HOSTED THE 15TH BIENNIAL OVARIAN CANCER RESEARCH SYMPOSIUM, BRINGING TOGETHER NEARLY 250 RESEARCHERS AND CLINICIANS FROM 11 COUNTRIES WHO CAME TO LEARN ABOUT THE...
IN SEPTEMBER 2024, THE RIVKIN CENTER HOSTED THE 15TH BIENNIAL OVARIAN CANCER RESEARCH SYMPOSIUM, BRINGING TOGETHER NEARLY 250 RESEARCHERS AND CLINICIANS FROM 11 COUNTRIES WHO CAME TO LEARN ABOUT THE LATEST IN OVARIAN CANCER RESEARCH. THE EVENT HOSTED A SESSION WITH PATIENT ADVOCATES; SCIENTIFIC SESSIONS COVERED THE BIOLOGY OF OVARIAN CANCER, PREVENTION, EARLY DETECTION, & INTERCEPTION, EMERGING THERAPEUTICS, NOVEL IMMUNOTHERAPIES, AND HEALTHCARE DISPARITIES. ON APRIL 30, 2024, THE RIVKIN CENTER ENDED ITS EDUCATION PROGRAM FOCUSED ON OVARIAN AND BREAST CANCER EDUCATION AND RETURNED TO A SOLE FOCUS ON OVARIAN CANCER - BOTH RESEARCH GRANTS AND BETTER SUPPORT FOR THOSE DIAGNOSED WITH OVARIAN CANCER IN THE PACIFIC NORTHWEST. FROM JANUARY TO MARCH 2024 THE EDUCATION TEAM SUPPORTED 15 COLLEGE-CAMPUS WORKSHOPS AND EIGHT PUGET SOUND COMMUNITY WORKSHOPS. COMMUNITY WORKSHOPS WERE HELD IN COORDINATION WITH MERCY HOUSING, MARY'S PLACE, FAMILYWORKS, WASHINGTON RHINESTONE CLUB, SEATTLE JEWISH FESTIVAL AND HERZL NER TAMID AND REACHED PRIMARILY PARTICIPANTS WHO BELONG TO HISTORICALLY UNDER-RESOURCED/UNDERREPRESENTED GROUPS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $1,700,018 | $1,284,232 | +0.3% |
| Expenses | $1,678,303 | $1,404,009 | +0.2% |
| Net Income | $21,715 | $-119,777 | -1.2% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| MOLLY O'CONNOR | CEO | 40.00 |
Officer
|
$161,600 | $24,082 | $185,682 |
| PAULINE MIDDLEHURST | DEVELOPMENT DIRECTOR (UNTIL 4/2024) | 40.00 |
Officer
|
$29,586 | $5,475 | $35,061 |
| MELISSA RIVKIN | PRESIDENT | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| AMY SING | VICE PRESIDENT | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| ALEX SMITH | SECRETARY | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| THOMAS BROWN | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| EVA CORETS | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| AUDREY COVNER | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| KRISTIN HAWES | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| BOB MAHLER | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| FERNANDA MUSA | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| KATERIE SCHEI | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| KATIE VAN KESSEL | MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| ANDREA REWITZ MIZER | MEMBER (UNTIL 6/2024) | 1.00 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $1,700,018 | $1,678,303 | $1,970,548 | $21,715 |
| 2023 | $1,284,232 | $1,404,009 | $1,949,824 | $-119,777 |
| 2022 | $1,484,984 | $1,297,053 | $2,071,817 | $187,931 |
| 2021 | $1,708,996 | $1,507,086 | $2,054,285 | $201,910 |
| 2020 | $1,531,882 | $1,808,055 | $1,689,610 | $-276,173 |
| 2019 | $2,197,898 | $2,944,228 | $1,851,779 | $-746,330 |
| 2018 | $3,083,390 | $2,432,795 | $2,630,978 | $650,595 |
| 2017 | $2,475,674 | $2,283,117 | $2,344,623 | $192,557 |
Compare RIVKIN CENTER FOR OVARIAN CANCER with other nonprofits in Washington and across the country.